Interleukin-17A expression in patients presenting with nasal polyposis

Braz J Otorhinolaryngol. 2013 Sep-Oct;79(5):616-9. doi: 10.5935/1808-8694.20130110.
[Article in English, Portuguese]

Abstract

Sinonasal polyposis (SNP) is a chronic inflammatory pathology of the nasal/paranasal cavities which affects from 1%-4% of the population. Although polyps seem to be a manifestation of chronic inflammation of nasal/paranasal sinus mucosa in both allergic and non-allergic subjects, the pathogenesis of nasal polyposis remains unknown. Interleukin-17A (IL-17A) is a key inflammatory cytokine in many disorders. Little attention has been paid to the role of IL-17A in chronic inflammatory disorders.

Objective: To investigate the expression of IL-17A in the SNP and verify if this expression is a marker of good or bad prognosis.

Method: Prospective study with 25 patients presenting with SNP were subjected to the immunohistochemistry technique. After a skin prick test, all patients were divided into atopic and nonatopic groups, and asthmatic or non-asthmatic.

Results: The IL-17A expression was observed in both atopic and nonatopic patients. The numbers of IL-17A positive cells were greater in nasal polyps of atopic patients than nonatopic (p = 0.0128).

Conclusion: These results indicate that IL-17A may play an important role in the pathology of SNP. Considering the inflammatory properties of IL-17A, this study suggests that it could increase susceptibility to atopy and asthma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Asthma / complications
  • Asthma / metabolism*
  • Biomarkers / metabolism
  • Case-Control Studies
  • Female
  • Humans
  • Immunohistochemistry
  • Interleukin-17 / metabolism*
  • Male
  • Middle Aged
  • Nasal Polyps / complications
  • Nasal Polyps / metabolism*
  • Prognosis
  • Prospective Studies

Substances

  • Biomarkers
  • Interleukin-17